Sheldon Litwin is a Cardiology physician affiliated with Medical University of South Carolina. OpenAlex indexes 309 publications with 15,962 citations (h-index 61); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
171 Ashley Ave
Charleston, SC 294258908
Telephone
843-792-1414Provider last certified this registry record 3 Nov 2025.
Clinical trials
- Effects of Body Mass Index on the Hyperemic Response to Regadenoson
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20254 payments$14,234openpaymentsdata.cms.gov ↗
- Edwards Lifesciences CorporationProgram year20251 payment
- Novo Nordisk IncProgram year20245 payments$13,409openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
68.7%Aldosterone antagonist (MRA)17.8%Spironolactone95%Eplerenone5%Part D<11 patientsLoop diuretic10.9%Furosemide64%Bumetanide36%Part D≥36 patients+ 14 more classes in this area
Metabolism & gastrointestinal
22.2%SGLT2 inhibitor14.9%Jardiance73%Farxiga27%Part D≥37 patientsGLP-1 receptor agonist6.6%Mounjaro44%Ozempic30%Wegovy26%Part D<11 patients+ 1 more class in this area
Blood & clotting
7.4%Factor Xa inhibitor6.2%Eliquis66%Xarelto34%Part D<11 patientsP2Y12 inhibitor1.2%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
New England Journal of Medicine
2024 - Dapagliflozin for heart failure according to body mass index: the DELIVER trial
European Heart Journal
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Tanya Turan, MD
Medical University of South Carolina
Michael Zile, MD
Medical University of South Carolina
Don Rockey, MD
Medical University of South Carolina
William Creasman, MD
Medical University of South Carolina
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”